556 related articles for article (PubMed ID: 35610531)
1. A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.
Collongues N; Becker G; Jolivel V; Ayme-Dietrich E; de Seze J; Binamé F; Patte-Mensah C; Monassier L; Mensah-Nyagan AG
Neurol Ther; 2022 Sep; 11(3):981-1042. PubMed ID: 35610531
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
Schneider R; Oh J
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Advances in Multiple Sclerosis.
Yang JH; Rempe T; Whitmire N; Dunn-Pirio A; Graves JS
Front Neurol; 2022; 13():824926. PubMed ID: 35720070
[TBL] [Abstract][Full Text] [Related]
4. Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKβ promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice.
Papazian I; Tsoukala E; Boutou A; Karamita M; Kambas K; Iliopoulou L; Fischer R; Kontermann RE; Denis MC; Kollias G; Lassmann H; Probert L
J Neuroinflammation; 2021 Sep; 18(1):222. PubMed ID: 34565380
[TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
[TBL] [Abstract][Full Text] [Related]
6. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration and neuroprotective agents in multiple sclerosis.
Fong JS; Rae-Grant A; Huang D
Recent Pat CNS Drug Discov; 2008 Nov; 3(3):153-65. PubMed ID: 18991805
[TBL] [Abstract][Full Text] [Related]
8. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Al-Izki S; Pryce G; Hankey DJ; Lidster K; von Kutzleben SM; Browne L; Clutterbuck L; Posada C; Edith Chan AW; Amor S; Perkins V; Gerritsen WH; Ummenthum K; Peferoen-Baert R; van der Valk P; Montoya A; Joel SP; Garthwaite J; Giovannoni G; Selwood DL; Baker D
Brain; 2014 Jan; 137(Pt 1):92-108. PubMed ID: 24287115
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in multiple sclerosis: a therapeutic approach.
Maghzi AH; Minagar A; Waubant E
CNS Drugs; 2013 Oct; 27(10):799-815. PubMed ID: 23955320
[TBL] [Abstract][Full Text] [Related]
10. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.
Ziemssen T
J Neurol; 2005 Nov; 252 Suppl 5():v38-45. PubMed ID: 16254701
[TBL] [Abstract][Full Text] [Related]
11. Statins and their potential targets in multiple sclerosis therapy.
Stüve O; Prod'homme T; Slavin A; Youssef S; Dunn S; Steinman L; Zamvil SS
Expert Opin Ther Targets; 2003 Oct; 7(5):613-22. PubMed ID: 14498824
[TBL] [Abstract][Full Text] [Related]
12. B cells and antibodies in progressive multiple sclerosis: Contribution to neurodegeneration and progression.
Fraussen J; de Bock L; Somers V
Autoimmun Rev; 2016 Sep; 15(9):896-9. PubMed ID: 27396817
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.
Paintlia AS; Paintlia MK; Singh I; Skoff RB; Singh AK
Glia; 2009 Jan; 57(2):182-93. PubMed ID: 18720408
[TBL] [Abstract][Full Text] [Related]
14. Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications.
Simkins TJ; Duncan GJ; Bourdette D
Curr Neurol Neurosci Rep; 2021 Apr; 21(6):26. PubMed ID: 33835275
[TBL] [Abstract][Full Text] [Related]
15. Efforts Towards Repurposing of Antioxidant Drugs and Active Compounds for Multiple Sclerosis Control.
Theodosis-Nobelos P; Rekka EA
Neurochem Res; 2023 Mar; 48(3):725-744. PubMed ID: 36385213
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design.
Kapoor R
Curr Opin Neurol; 2006 Jun; 19(3):255-9. PubMed ID: 16702831
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
Arnon R; Aharoni R
J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
[TBL] [Abstract][Full Text] [Related]
18. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options.
Andravizou A; Dardiotis E; Artemiadis A; Sokratous M; Siokas V; Tsouris Z; Aloizou AM; Nikolaidis I; Bakirtzis C; Tsivgoulis G; Deretzi G; Grigoriadis N; Bogdanos DP; Hadjigeorgiou GM
Auto Immun Highlights; 2019 Dec; 10(1):7. PubMed ID: 32257063
[TBL] [Abstract][Full Text] [Related]
19. New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration.
Podbielska M; O'Keeffe J; Pokryszko-Dragan A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298940
[TBL] [Abstract][Full Text] [Related]
20. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Arun T; Tomassini V; Sbardella E; de Ruiter MB; Matthews L; Leite MI; Gelineau-Morel R; Cavey A; Vergo S; Craner M; Fugger L; Rovira A; Jenkinson M; Palace J
Brain; 2013 Jan; 136(Pt 1):106-15. PubMed ID: 23365093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
